FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pharmacology, toxicology, individual therapy of psychoactive substance poisoning in adolescents, and can be used to select a treatment regimen for adolescents in case of poisoning with unknown psychoactive substances. Treatment is selected differentially, according to the proposed pharmacological group of drugs based on an assessment of the patient's condition: if depression of the central nervous system is observed with a normal pupil diameter, cholinergic toxidrom and poisoning with benzodiazepines or barbiturates are judged, while, if ataxia, dysarthria, muscular hypotension is detected, poisoning is diagnosed benzodiazepines and prescribe intravenous infusion of meglumine sodium succinate at a dose of 10 ml/kg per hour and flumazenil at a starting dose of 0.05-0.1 mg/kg and a daily dose of 110 mg, if arterial hypotension, hypersalivation, bronchorrhea are detected, barbiturate poisoning is diagnosed and prescribed infusion of meglumine sodium succinate at a dose of 10 ml/kg per hour; if depression of the central nervous system and miosis, shallow breathing, absence of bowel sounds, bradypnea are observed, the manifestation of opioid toxidrom is judged and opioid poisoning is diagnosed and meglumine sodium succinate is prescribed at a dose of 10 ml/kg per hour and naloxone at a starting dose of 0.4 mg 1 ml, and if there is no effect after 2 minutes, naloxone 0.3 mg/kg is additionally administered; if vasomotor excitation, mydriasis, hypertension, hyperhidrosis, hyperthermia are observed, sympathomimic toxidrome is judged, poisoning with psychoactive stimulants, meglumine sodium succinate is prescribed 10 ml/kg per hour.
EFFECT: method provides an opportunity to start therapy before performing laboratory tests, to differentiate the pharmacological group of drugs that poisoned the teenager, to assess the need for a certain set of therapeutic measures in the intensive care unit or dynamic monitoring in the pediatric department by assessing the patient's condition according to the totality of clinical manifestations.
1 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREVENTING ENDOTHELIAL DAMAGE IN CRITICALLY ILL PATIENTS | 2023 |
|
RU2812594C1 |
METHOD OF ANTIOXIDANT STATUS CORRECTION IN CHILDREN EPILEPSY MONOTHERAPY | 2019 |
|
RU2712146C1 |
METHOD FOR TREATING THE CASES OF DRUG ADDICTION | 2003 |
|
RU2288717C2 |
METHOD OF TREATING SEVERE ACUTE PSYCHOPHARMACEUTICAL POISONING IN CHILDREN | 2014 |
|
RU2570399C1 |
METHOD FOR DIFFERENTIATED SELECTION OF THERAPY IN ACUTE DRUG POISONING IN CHILDREN | 2021 |
|
RU2766403C1 |
METHOD OF EVALUATING SEVERITY OF PATIENTS WITH OPIOID POISONING | 2009 |
|
RU2413946C2 |
BALANCED INFUSION SOLUTION | 2014 |
|
RU2549448C1 |
METHOD FOR CORRECTING COGNITIVE FUNCTIONS DURING MONOTHERAPY OF EPILEPSY IN CHILDREN | 2020 |
|
RU2763332C1 |
APPLICATION OF BETA-HYDROXYBUTYRATE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR PREPARATION OF MEDICATION WHICH POSSESSES CYTOPROTECTIVE ACTIVITY, INCLUDING NEUROPROTECTIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC, ANTI-HYPOXIC, ANTI-STRESS, ACTOPROTECTIVE AND ADAPTOGENIC ACTIVITY, MEDICATION AND METHOD OF PREVENTION, RELIEF AND TREATMENT BY MEANS OF SAID MEDICATION | 2009 |
|
RU2426535C2 |
METHOD OF ALCOHOLIC ABSTINENCE SYNDROME REDUCTION | 2006 |
|
RU2327474C1 |
Authors
Dates
2022-11-23—Published
2022-04-07—Filed